1020 First Avenue
King of Prussia
About CSL Behring
As the third largest global biotechnology company with employees in more than 35 countries, CSL Behring is focused on serving patients with serious and rare diseases, including coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease and neurological disorders. We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge and support future medical research.
CSL Behring's dynamic environment fosters innovation and attracts the best and brightest who share a commitment to helping save lives. People here are free to live their Promising FUTURES where they can fulfill their individual career aspirations and realize their potential.
CSL Behring is committed to diversity and inclusion, both of which underpin our Values of patient focus, innovation, collaboration, integrity and superior performance. We believe that by harnessing and honoring the unique capabilities, experiences and perspectives of our people, we are better able to serve our patients.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited, headquartered in Melbourne, Australia, employs more than 27,000 people, and provides its life-saving medicines in more than 70 countries.
For more information visit www.cslbehring.com. Help us deliver on our promise to save lives and protect the health of people around the world. Promising FUTURES start at CSL Behring!
Stock Symbol: CSL
Stock Exchange: Australian Securities Exchange
An overview of the CSL Behring Fermentation Facility at Penn State
286 articles with CSL Behring
CSL Behring, a global biotherapeutics leader, announced results of a Phase 2 clinical trial for garadacimab, an investigational novel Factor XIIa-inhibitory monoclonal antibody in development as a preventive treatment in hereditary angioedema.
CSL Behring, based in King of Prussia, Pennsylvania, is acquiring Vancouver, British Columbia-based Vitaeris. The two companies inked a strategic partnership in 2017 to accelerate the development of Vitaeris’s clazakizumab. At that time, CLS Behring also had an option to acquire Vitaeris, the the...
CSL Behring and Seattle Children's Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases
Initially, the alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia (XLA) [02-June-2020] SEATTLE and KING of PRUSSIA, Pa. , June 2, 2020 /PRNewswire/ -- Seattle Children's Research Institute, one of the top pediatric research institutio
CSL Behring has developed a number of strategies to address COVID-19, the disease caused by the novel coronavirus that originated in China and spread across the globe in a matter of months.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 8, 2020.
BrightInsight and CSL Behring Announce Global Digital Health Partnership to Improve Treatment Experience for Patients with Rare Diseases
CSL Behring selects the BrightInsight Platform to build and manage its digital health solutions within a regulatory-compliant environment
CSL Behring Announces Results from Three Analyses of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) in Primary Immunodeficiency (PI)
Study examined the safety and tolerability of faster infusion rates and higher infusion volumes, as well as the feasibility of a new manual push administration method [21-April-2020] PHILADELPHIA , April 21, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that a clinical study examining faster infusion rates and higher volumes than curre
COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB's novel platform technology, on-track for clinical evaluation as early as summer [08-April-2020] KING OF PRUSSIA, Pa. and SIOUX FALLS, S.D. , April 8, 2020 /PRNewswire/ -- Global biotherapeutics leader, CSL Behring and innova
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.
Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy
Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 6, 2020.
University City Science Center partnership with CSL Behring accelerates the search for new biotherapies at the University of Pittsburgh and the University of Delaware
- Universities awarded $250,000 research grants as part of the CSL Behring-Science Center Research Acceleration Initiative -
PRIVIGEN® (Immune Globulin Intravenous (Human), 10% Liquid) Granted Orphan-Drug Designation for the Investigational Treatment of Systemic Sclerosis (SSc)
CSL Behring advances Ig clinical trial program to address unmet need in treating serious autoimmune disease
This year's rankings based on independent survey of more than 60,000 U.S. employees across industries
HIZENTRA® (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
First and only subcutaneous immunoglobulin (SCIg) approved for maintenance therapy in CIDP qualifies for marketing exclusivity
Here are five high-quality examples of major bio organizations’ efforts to showcase their commitment to providing a positive D&I work environment.
Netherlands-based Pharming Group NV has denied any involvement in a potential theft of intellectual property belonging to CSL Behring from Joseph Chiao, who recently joined Pharming as medical director.
Pharming categorically denies having had any involvement in the alleged abstraction of proprietary information by Dr Joseph Chiao from his former employer CSL
GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.
CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019
Novel real world evidence for AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain] and IDELVION® ® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein] to be highlighted [01-July-2019] MELBOURNE, Australia , July 1, 2019 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that the company will support the presentation of new